Life Science Nation Newsletter  | March 9,  2017  |  Issue 204

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Mar. 2  - Mar. 8)
Invests in Highly Differentiated Novel Therapeutics, Devices and Diagnostics
Looks Worldwide for Treatments for Ultra Rare Diseases
Invests in Brain Diseases, Oncology and Ophthalmology
Opportunistically Invests in Medtech, Biotech, Healthcare IT and Diagnostics
In This Issue
News
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

LSN Book

LSN Videos
By Michael Quigley, VP of Market Research, LSN

As RESI gears up for its second landing on MaRs in Toronto this April 4th we are proud to announce our latest batch of life science/health tech companies that will be participating in the RESI Innovation Challenge.

30 companies from across North America, hand selected by LSN's scientific and commercial review team, will compete directly on merits of innovation and commercial viability. Past RESI events have seen as many as 50% of innovation challenge contestants go on to receive funding or significant partnerships within a year from the competition.

From companies helping to detect oncoming seizures to those developing cost effective ways of growing blood stem cells, this diverse class of competitors is sure to impress. Come check them our yourself in the Exhibition Hall at RESI on MaRs on April 4th!

Therapeutic











Diagnostic





Medical Device








Healthcare IT













By James Huang, Research Analyst, LSN
Claire Jeong, Research Analyst, LSN

Last week, LSN looked into the emerging life science hubs in Toronto and NYC to assess where the "Third Coast" of life sciences might emerge. This week, we'll take a look at two more cities that are looking to become beacons for the life science industry: Houston and Seattle. 

The emergence of Texas Medical Center's innovation programs has put Houston on the life science map. In 2015, JLABS @ TMC opened to provide wet lab space for young biotech companies. In Seattle, Juno Therapeutics has recently put the city back into the spotlight. Both cities are home to major research centers, and are looking to convert their scientific acumen into further commercial progress. Here's how they stack up.

Houston Seattle
Research institutions Texas Medical Center comprises over 40 institutions, including major research centers such as MD Anderson, Baylor, Texas Children's, and Rice University Major institutions include the University of Washington (UW), Fred Hutch Cancer Research Center, Allen Institute for Brain Science, and Seattle Biomedical Research Institute.
Pharma presence Johnson & Johnson have opened JLABS @ TMC. Alcon, Lonza, Mylan, Bayer and Novartis also have facilities in Houston. Pharma companies with Seattle operations include Celgene, Bristol-Myers Squibb, Novo Nordisk and Gilead Sciences. Juno Therapeutics is based in Seattle.
Local investors The LSN Investor Platform tracks 52 life science investors based in Texas. The LSN Investor Platform tracks 18 life science investors based in Washington State.
Government support CPRIT (Cancer Prevention and Research Initiative of Texas) provides $3 billion in funding From 2005-2015, the Life Sciences Discovery Fund provided support to biotech startups. This continued into 2017 as a competitive grant program.
Startup companies The LSN Company Platform tracks 69 biotech and 123 medtech startups in Texas. The LSN Company Platform tracks 61 biotech and 35 medtech startups in Washington State.

Please place your vote for the new Third Coast:




  
By Christine A. Wu, Senior Research Analyst, LSN

Despite therapeutic companies' high-risk development timeline, investors continue to remain focused on investing in biotechnology, seeing its long-term impact and enormous potential in the healthcare industry. Along with the technology, entrepreneurs need to also consider capital intensity, fundraising and milestone timeline, management team, and endpoint selections, among other topics beyond the science.

LSN has assembled five active investors specifically interested in early-stage biotech therapeutics for RESI Toronto, occurring on April 4th. Held in the heart of Canada's healthcare innovation hub, MaRS Discovery District. 

The Early Stage Therapeutic Investors Panel will be moderated by Mark Day , Head, CNS Virtual Discovery of Purdue Pharma, and will be joined by:
  • Kelly Holman, Co-Founder and Managing Partner, Genesys Capital
  • Inès Holzbaur, General Partner, AmorChem Financial
  • David O'Neill, Vice President, Business Development, Fight Against Cancer Innovation Trust
  • Nicola La Monica, Senior Director, Infectious Disease Scientific Innovation, Janssen Pharmaceutical Companies of Johnson & Johnson